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We have identified seven ERK-related proteins
(“ERPs”), including ERK2, that are stably associated in
vivo with AP-1 dimers composed of diverse Jun and Fos
family proteins. These complexes have kinase activity.
We designate them as “class I ERPs.” We originally hy-
pothesized that these ERPs associate with DNA along
with AP-1 proteins. We devised a DNA affinity chroma-
tography-based analytical assay for DNA binding, the
“nucleotide affinity preincubation specificity test recog-
nition” (NAPSTER) assay. In this assay, class I ERPs do
not associate with AP-1 DNA. However, several new
“class II” ERPs do associate with DNA. p41 and p44 are
ERK1/2-related ERPs that lack kinase activity and asso-
ciate along with AP-1 proteins with AP-1 DNA. Class I
ERPs and their associated kinase activity thus appear to
bind AP-1 dimers when they are not bound to DNA and
then disengage and are replaced by class II ERPs to
form higher order complexes when AP-1 dimers bind
DNA. p97 is a class III ERP, related to ERK3, that asso-
ciates with AP-1 DNA without AP-1 proteins. With the
exception of ERK2, none of the 10 ERPs appear to be
known mitogen-activated protein kinase superfamily
members.
Regulatory transcription factors are of central importance in
mediating cellular responses to environmental stimuli by coor-
dinately regulating genes encoding proteins and enzymes that
implement the responses. Activator protein-1 (AP-1)1 is a tran-
scription factor that binds to and regulates genes containing
TGAg/cTCA consensus cis-regulatory elements (referred to
here as “AP-1 DNA-binding sites” or “AP-1 DNA”) (1, 2) that
generally lie within gene promoter regions. Regulation by AP-1
has been demonstrated in diverse cellular processes, including
growth, differentiation, tissue remodeling, and apoptosis (Ref.
3 and references therein).
Altered expression and DNA binding of AP-1 subunits, and
inappropriate transactivation of AP-1-dependent effector
genes, are events implicated in the pathogenesis of numerous
cancers and in cardiovascular, neurological, and other disease
states (4–6). AP-1 activation is a pivotal event in mediating
cancer susceptibility and neoplastic transformation in response
to endogenous and extracellular stimuli, including hormones,
growth factors, tumor promoters, and many other carcinogenic
agents (Refs. 7–9 and see Ref. 3 for review). Many genes asso-
ciated with neoplastic transformation harbor AP-1 sites, in-
cluding genes encoding matrix-degrading enzymes, differenti-
ation factors, and mitogenic agents.
AP-1 is a dimer composed of proto-oncogene products en-
coded by the jun and fos families. The jun family consists of
c-jun, junB, and junD, and the fos family consists of c-fos, fra-1,
fra-2, and fosB. Dimers can be Jun family-Jun family ho-
modimers or Jun family-Fos family heterodimers, generating
18 possible complexes via leucine zipper dimerization motifs
within the Jun and Fos subunits. AP-1 dimers bind DNA via a
basic region immediately adjoining the leucine zipper, forming
a composite region in the proteins referred to as the “bZIP”
motif (see Ref. 10 for review). Gene expression is regulated by
transactivation domains within the AP-1 subunits, which mod-
ulate the efficiency of RNA polymerase II transcriptional
initiation.
The transactivation and DNA binding activities of AP-1 are
modulated by protein kinase cascades that terminate in phos-
phorylation of Jun and Fos family proteins. Members of the
mitogen-activated protein kinase superfamily (“MAP kinases”)
are thought to be responsible for phosphorylation of AP-1 pro-
teins in vivo (see Ref. 11 for review). Ligand-activated receptors
indirectly stimulate kinase activity of MAP kinase kinase ki-
nases (MAPKKKs) that activate MAP kinase kinases (MAP-
KKs), which in turn activate MAPKs to phosphorylate their
targets, often transcription factors such as Jun and Fos (see
Refs. 12 and 13 for review). The MAP kinase superfamily is
composed of several subfamilies. Each subfamily consists of a
discrete signaling module with distinct MAPKKK and MAPKK
components. The most well characterized members of the ERK
subfamily are ERK-1 and ERK-2 and, to a lesser degree, p63/
ERK-3 and human p97/ERK3 (14–16). The Jun kinase (JNK)/
stress-activated protein kinase (SAPK) family includes three
major members, JNK1, JNK2, and JNK3. The p38 family in-
cludes p38, p38, p38, and p38 (Ref. 13 and references
therein). Other MAPKs include ERK4, ERK-5/BMK1, ERK6,
and ERK7 (17–21). ERKs are primarily activated by mitogenic
agonists such as TPA, epidermal growth factor, or fibroblast
growth factor, whereas JNK/SAPKs are primarily activated by
stress factors such as UV light, tumor necrosis factor, osmotic
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and heat shock, and inflammatory agents (13). p38 MAPKs are
activated by endotoxic lipopolysaccharide and, like JNK/
SAPKs, by environmental stress, osmotic shock, and inflamma-
tory agents (13). A system of several parallel MAPK signal
transduction pathways has thus emerged.
MAPKs regulate a number of transcription factors, including
Elk/TCF, NFAT, ATF, and AP-1. ERKs and JNK/SAPKs me-
diate activity of AP-1 in response to mitogenic and stress fac-
tors, respectively. ERKs phosphorylate c-Jun, JunD, Fra-1,
Fra-2, and FosB, and JNKs phosphorylate c-Jun and JunD
(22–26). JNK binding to docking sites on c-Jun and JunD has
been reported (25). Both ERKs and JNKs regulate AP-1 trans-
activation and mediate AP-1-dependent neoplastic transforma-
tion (27–30).
Interactions between AP-1 and many other proteins have
been identified. Multiple members of the bZIP AP-1 superfam-
ily, and of the nuclear hormone receptor transcription factor
superfamily, have been found in association with AP-1. Other
transcription factors that interact with AP-1 include NFAT,
Ets, YY1, TATA-binding protein, and Myo D (10, 31). Coacti-
vators and repressors that bind to AP-1 include CBP/p300,
JAB1 along with eight other proteins in the COP 9 complex,
ASC-2, and JDP2 (32–37). The retino-blastoma protein pRb
also binds AP-1 proteins (38). The diverse array of regulatory
molecules that interact with Jun-Fos complexes underscores
the exquisite circuitry dedicated to controlling AP-1 in its piv-
otal position as a regulator of essential cellular functions.
Previously we identified several ERK-related proteins
(ERPs), including the ERK2 MAP kinase, that bind in vivo to
AP-1 complexes containing c-Jun and c-Fos (39). In the present
study we have found that five Jun and Fos family members
form complexes with seven distinct ERK2-related ERPs, and
these ERPAP-1 complexes have associated kinase activity. To
account for the multiplicity and stability of these complexes, we
hypothesized that in addition to a simple enzyme-substrate
relation, ERPAP-1 complexes could interact with genes con-
taining transcription regulatory AP-1 DNA recognition se-
quences. If this is the case, we should be able detect multicom-
ponent ERPAP-1DNA complexes. To test this hypothesis, we
devised a simple DNA affinity chromatography-based analyti-
cal assay, the “NAPSTER” assay, for specific association with
DNA sequences. By these means we identified p41 and p44, two
additional ERPs related to ERK2 that associate with the AP-1
DNA along with AP-1 proteins. In contrast, the first seven
ERPs bind AP-1 proteins only when they are not bound to the
DNA. We also identified p97, a 10th ERP related to ERK3, that
associates with AP-1 DNA without AP-1 proteins. We therefore
describe three distinct classes of ERPs as follows: seven class I
ERPs that bind AP-1 dimers without DNA, two class II ERPs
that associate along with AP-1 with DNA, and one class III
ERP that associates with AP-1 DNA without AP-1 dimers.
EXPERIMENTAL PROCEDURES
Antibodies—Antibodies and corresponding peptide antigen competi-
tor peptides used for immunoblotting and immunodepletions included
c-Jun, JunB, JunD, c-Fos, Fra-1, Fra-2, FosB, p38, JNK,
ERK1, ERK5/BMK1, ERK6, and ERK3 D23 (which also recognizes
human p97/ERK3) against amino acids 303–325 in rat ERK3, all of
which were from Santa Cruz Biotechnology. Unless otherwise noted,
antibodies used in experiments were from Santa Cruz Biotechnology.
Other antibodies included anti-rat ERK3 “C” against amino acids 427–
442 of rat ERK3, anti-human ERK3 “F” against amino acids 543–721 of
human ERK3, and anti-rat ERK3 “I15” against amino acids 353–367 of
rat ERK3. Antibodies from other sources include JunD (“KG”) against
full-length mouse JunD (40), c-Jun-(948-4) against the C-terminal 82
amino acids of avian c-Jun (41), mouse monoclonal anti-ERK1/2 anti-
body 1B3B9 (Upstate Biotechnologies, Inc., Lake Placid, NY), Fos-(75–
155) against amino acid residues 75–155 of avian v-Fos (Upstate Bio-
technologies, Inc.), and Fra-1-(1–276) against amino acids 1–276 of
Fra-1 (42), all of which were used in immunoprecipitations and two-
dimensional gels. Anti-ERK1-III is against amino acids 63–98 in sub-
domain III of rat ERK1 (Upstate Biotechnologies, Inc.).
Reagents—Reagents and supplies not described herein were pur-
chased from vendors cited in Bernstein and Walker (43).
Cell Culture—Human HT29 adenocarcinoma cells were purchased
from American Type Culture Collection (ATCC, Manassas, VA). For
routine passage, HT29 cells were plated at 1:20 in T25 flasks in Dul-
becco’s modified Eagle’s medium (Mediatech Cellgro, Herndon, VA)
containing 10% heat-inactivated fetal bovine serum (FBS, Summit Bio-
technology, Inc., Fort Collins, CO) and passaged every week with media
changes after 4 days. JB6 Cl307b cells were grown and passaged as
described (44).
Preparation of Nuclear Extracts—HT29 cells for nuclear extracts
(“NE”) were plated in 150-mm tissue culture dishes (Nunc, Inc., Naper-
ville, IL) at a density of 6  106 cells per dish in Dulbecco’s modified
Eagle’s medium with 10% FBS and allowed to grow for 5 days with one
media change 4 days after plating. Cells were routinely treated for 90
min with 10 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma)
in fresh media containing 10% FBS, unless otherwise noted. Cells were
then harvested, and NE was prepared as described (43).
Preparation of AP-1 DNA Affinity Beads—Biotinylated AP-1 oligo-
nucleotide (“oligo”) derived from nucleotides from the gibbon ape leu-
kemia virus-long terminal repeat (GALV-LTR), contained a wild type
AP-1 sequence (5-agccagagaaatagatgagtcaacagc-3). In this paper we
refer to this sequence as the AP-1 DNA-binding site or AP-1 DNA. This
sequence and the inverse complementary oligo were custom-synthe-
sized by Macromolecular Resources (Fort Collins, CO). Binding of an-
nealed, double-stranded biotinylated oligo to streptavidin beads (Roche
Molecular Biochemicals, Indianapolis, IN) was performed according to
the manufacturer’s instructions.
AP-1 DNA Affinity Chromatography—AP-1 DNA affinity chromatog-
raphy was performed as described by Lee et al. (1) with major modifi-
cations designed to achieve rapid analytical scale isolation of labile and
multicomponent protein-DNA complexes. For small scale experiments,
as little as 30 g of input NE protein and 6 g of DNA on beads were
used (1:5 ratio of DNA:input protein). For large scale experiments, 3–5
mg of NE protein and 150–250 g of DNA on beads were used (1:20
ratio of DNA:input protein). Whole nuclear extracts (NE) were dialyzed
into Buffer Z (0.1 M KCl, 25 mM HEPES, pH 7.8, 12.5 mM MgCl2, 1 mM
dithiothreitol, 20% glycerol, v/v, 0.1% v/v Nonidet P-40, 0.1 M ZnCl2, 5
mM NaF, 1 mM sodium orthovanadate, 0.1 mM phenylmethylsulfonyl
fluoride). AP-1 and associated proteins were then isolated by single-step
batchwise AP-1 DNA affinity chromatography to promote maximal
stability and detection of associated proteins. Dialyzed NE was incu-
bated for 75 min at 4 °C on a rotating clip wheel in the presence of 6
g/ml poly(dI/dC) with AP-1 affinity beads. Beads were centrifuged for
1 min in an Eppendorf centrifuge at 4 °C, and the supernatant was
removed. For small scale assays, beads were washed three times with
Buffer Z; bound material was eluted by boiling the beads in SDS sample
buffer, and the boiled material was directly loaded in SDS-PAGE. For
larger scale assays, beads were washed five times in Buffer Z and then
AP-1 and associated proteins eluted in Buffer Z containing 1 M KCl by
twirling on a rotating clip wheel for 30 min at 4 °C.
The NAPSTER Assay—To assess specificity of binding to the AP-1
DNA sequence, we developed an assay that we termed the nucleotide
affinity preincubation specificity test recognition assay (the NAPSTER
assay). The NAPSTER assay consists of a matched set of three samples.
For sample I, whole NE is directly chromatographed batchwise with
AP-1 DNA beads. For sample II, NE is preincubated for 15 min at 4 °C
with a 2.5-fold molar excess of wild type AP-1 DNA oligo (relative to
moles of DNA on the beads) before batchwise DNA affinity chromatog-
raphy. For sample III, NE is preincubated for 15 min at 4 °C with a
2.5-fold molar excess of mutant oligo (5-agccagagaaatagaggagtctacagc-
3; mutant AP-1 core sequence GGAGTCT, mutations underlined), be-
fore chromatography. After chromatography, beads are washed and
directly loaded in SDS-PAGE or subjected to elution procedures as
described above.
SDS-PAGE and Immunoblotting—SDS-PAGE and immunoblotting
were performed as described (39, 43).
Peptide Competition Assays—Peptide competition assays for immu-
noblotting and immunoprecipitations were performed using a 25-fold
molar excess of peptide as described (39, 43).
Preparation of Recombinant Proteins—A full-length recombinant hu-
man p97/ERK3 cDNA sequence (“rhERK3”) was cloned into the pET3C
vector (Stratagene, La Jolla, CA). Thirty cycles of polymerase chain
reaction were performed to amplify a linear BamHI-EcoRI rhERK3
DNA fragment containing the full-length ERK3 gene from plasmid
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pGEX2T-ERK3, using forward primer 5-agggtttccatatggcagagaaattt-
g-3 and reverse primer 5-tttgtgtgcatatgacatgccagttaa-3. This method
enabled in-frame insertion of the gene into the NdeI site of the vector.
Recombinant hERK3 was expressed in BL21 Codon Plus bacteria
(Stratagene, Inc., La Jolla, CA) according to the manufacturer’s
instructions.
Glutathione S-transferase-JunD (GST-JunD; see Ref. 45), a mouse
JunD fusion construct, was expressed in DH5 bacteria. Expressed
JunD was purified from bacterial extracts by GST affinity chromatog-
raphy with glutathione-agarose beads (Sigma) and eluted with 15 mM
glutathione (Sigma). pGCTD, a GST fusion construct containing the
mouse gene encoding the C-terminal domain of RNA polymerase II,
(“CTD”; see Ref. 46) was expressed, and GST-CTD fusion protein was
purified on the GST affinity column.
V8 Proteolytic Digestion Assay of p97 and Recombinant ERK3—V8
protease digest analyses were performed on p97 protein isolated by
batchwise DNA affinity chromatography from 20 mg of nuclear ex-
tract protein. Proteins isolated on affinity beads were eluted in 1 M
KCl and precipitated in 10% w/v trichloroacetic acid at 4 °C. Precip-
itated protein was run in denaturing and reducing SDS-PAGE, and
the p97 band was excised from the gel. Recombinant human ERK3
was also run in SDS-PAGE and similarly excised for V8 analyses.
Excised p97 and recombinant human ERK3 bands were subjected to
V8 protease digestion with 0.04 units of endoproteinase Glu-C (V8
protease; Roche Molecular Biochemicals) per lane, according to pro-
cedures described previously (39, 47).
Immunodepletion Assay—Samples either underwent two rounds
(“double depletion”) or three rounds (“triple depletion”) of immu-
nodepletion. For double depletions, 3.2 mg of NE per sample was
dialyzed against Buffer Z and incubated for 90 min with an antibody
mix consisting of 20 g of c-Jun, 20 g of JunD (Santa Cruz Biotech-
nology), and 10 l of JunD (KG), all of which had been dialyzed against
Buffer Z for 45 min at 4 °C. Samples were then incubated with 25 l of
protein A-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4 °C
with constant mixing. The procedure was repeated a second time to
obtain double depleted samples. For triple depletions, 5.1 mg of dia-
lyzed NE was preincubated for 90 min at 4 °C with an antibody mix
consisting of 20 g of c-Jun, 20 g of JunB, 20 g of JunD, 10 l of
JunD (KG), 20 g of c-Fos, 20 g of FosB, 20 g of Fra-1, and 20
g of Fra-2, followed by incubation with protein A-Sepharose for 1 h at
4 °C. This procedure was repeated twice to obtain triple depleted sam-
ples. Control samples did not contain antibody mix but underwent
depletion with protein A-Sepharose alone. Samples were then pread-
sorbed to reduce nonspecific binding by batchwise DNA affinity chro-
matography with beads containing streptavidin-linked mutant AP-1
oligo. Immunodepleted samples were subjected to the NAPSTER assay.
Immunoprecipitations—For two-dimensional gels and immunodeple-
tion assays, immunoprecipitations were performed as described (see
above and Ref. 39). For kinase assays and Western blots, Dynal protein
A magnetic beads (Dynal, Oslo, Norway) were preadsorbed for 30 min at
room temperature with 5 g of antibody in 0.1 M Phosphate Buffer, pH
8.2. Samples were incubated for 1 h with 400–500 g of dialyzed NE at
4 °C with constant twirling and then washed 3 times with Dulbecco’s
phosphate-buffered saline (Life Technologies, Inc.), according to the
manufacturer’s instructions.
Protein Kinase Assays—Protein kinase assays were performed on
immunoprecipitated and DNA affinity-purified proteins using a MAP
kinase assay kit with the classic MAP kinase substrate myelin basic
protein (MBP; Upstate Biotechnology, Inc.) with minor modifications of
the manufacturer’s protocol. Kinase assays of immunoprecipitated pro-
teins bound to Dynal beads were performed directly after washing
steps, without elution. For kinase assays of DNA-binding proteins,
nuclear extracts were dialyzed, subjected to batchwise AP-1 DNA af-
finity chromatography with mutant AP-1 beads to eliminate nonspe-
cifically associated material, and then subjected to batchwise DNA
affinity chromatography with beads harboring a wild type AP-1 DNA
sequence. Prior to assay, proteins bound to AP-1 DNA affinity beads
were eluted with a 2.5-fold molar excess of wild type AP-1 oligo to
maximize the specificity and the signal to noise ratio of the assay.
Elution was performed in 30 l of Kinase Assay Buffer (20 mM MOPS
pH 7.2, 25 mM -glycerophosphate (Sigma), 5 mM EGTA, 1 mM sodium
orthovanadate, 1 mM dithiothreitol) containing 40 g wt oligo at 4 °C for
30 min. Kinase assays were performed in a 50-l reaction consisting of
10 l of substrate (20 g of MBP or 1 g of recombinant c-Jun (Upstate
Biotechnologies, Inc.), 1 g of recombinant c-Fos, 10 g of histone H1
(Roche Molecular Biochemicals), 10 g of histone H3 (Roche Molecular
Biochemicals), GST-CTD, or GST-JunD; 10 l of [-32P]ATP mixture (1
l of 10 mCi, 6000 Ci/mmol; Amersham Pharmacia Biotech) diluted
with proteins eluted in 9 l of 75 M MgCl2 and 500 M ATP in Assay
Buffer), and 30 l of Kinase Assay Buffer for 15 min at 30 °C.
In Vivo Metabolic Labeling—In vivo metabolic labeling of JB6 Cl30
7b cells with Translabel (ICN, Inc., Costa Mesa, CA) was performed as
described (39). In vivo metabolic labeling of HT29 cells with Tran35S-
label was performed as described (39), except that labeling was done
overnight in cells plated at 6  106 cells/150-mm tissue culture dish.
Two-dimensional Gels—Two-dimensional non-equilibrium pH gradi-
ent gel electrophoresis (NEPHGE two-dimensional gels) was performed
as described (39). pH 3.5 to 10 and pH 5.0 to 7.0 ampholines were from
Pierce.
RESULTS
Immunoprecipitations with Anti-Jun and -Fos Antibodies
Detect ERK2 and Numerous Associated ERK-related Proteins
Bound in Vivo to Numerous AP-1 Dimerization Partners—To
determine whether ERK-related proteins (ERPs) interact in
vivo with AP-1 components, we performed immunoprecipita-
tions of 35S-metabolically labeled mouse epidermal JB6 Cl30 7b
and human HT29 colon adenocarcinoma whole cell extracts
with MAP kinase and AP-1 antibodies, followed by comparative
two-dimensional gel electrophoresis (two-dimensional gels). As
shown in Fig. 1, the PAN-ERK antibody ERK1-III immuno-
precipitates ERK2, since a major spot immunoprecipitated by
ERK1-III has identical mobility to ERK2 immunoprecipitated
by specific anti-ERK2 (compare protein spots in Fig. 1, panels
1 and 2; see Ref. 39). Immunoprecipitation of whole cell ex-
tracts with ERK1-III followed by Western blots with specific
antibodies against ERK2 corroborates these data (39). Several
other ERPs immunoprecipitated by ERK1-III are also detected
and are designated by their molecular weights as p49, p65, and
p100 as well as p38, p36, and p33 (B–D, respectively in Fig. 1,
where this p38 protein is not the p38 MAP kinase, see below).
These ERPs are specifically immunoprecipitated with ERK1-
III since antibody preincubation with the ERK1-III peptide
antigen, but not a heterologous peptide, abolishes immunopre-
cipitation of these proteins (panel 1, Fig. 1). Spots X, Y, and E
are ERK-related proteins specifically immunoprecipitated with
ERK1-III that are not coimmunoprecipitated with antibodies
against AP-1 species.
Immunoprecipitation with c-Fos and with Fra-1 immuno-
precipitates c-Fos and Fra-1 and coprecipitates AP-1 partners
c-Jun and JunD (panels 1 and 2 of Fig. 1). c-Jun immunopre-
cipitates AP-1 dimers containing the dimerization partner
Fra-2 in JB6 cells and c-Fos in HT29 cells (panel 2, Fig. 1).
Comparison of protein spots coprecipitated along with c-Jun,
c-Fos, and Fra-1 to proteins immunoprecipitated by the PAN-
ERK MAP kinase antibody ERK1-III shows that many ERK-
related proteins are coimmunoprecipitated with Fra-1 and c-
Jun. We collectively refer to these seven ERPs as class I ERPs.
These include proteins p100 (with c-Fos), p65 (with Fra-1), p49
(with c-Fos and c-Jun), proteins ERK2, p38 (B), p36 (C), and
p33 (D) (with c-Jun, c-Fos, and Fra-1), and p36 (C; with c-Jun
and Fra-1). Coimmunoprecipitation of ERPs p49, ERK2, and
p38 with c-Jun and c-Fos is also observed with extracts from
human HT29 colon adenocarcinoma cells, demonstrating that
ERPAP-1 complexes also exist in this cell type (Fig. 1, panel 2).
p49 and p38 were also detected in one-dimensional SDS-PAGE
by Western immunoblotting of JunD immunoprecipitates
from HT29 cells (not shown), thus corroborating the results
from two-dimensional gels. These data demonstrate the asso-
ciation of multiple ERPs with diverse AP-1 components in both
JB6 epidermal cells and HT29 colon adenocarcinoma cell types.
Several ERPs are in the general molecular weight ranges of
known MAPKs. We therefore performed experiments to deter-
mine whether these ERPs share identity with these MAPKs,
particularly those for which there is sufficient homology within
subdomain III (the region of ERK1 against which the peptide
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antibody was made) to expect immunological reactivity with
the ERK1-III antibody. ERK3, ERK4, and the JNK family
members JNK 1–3 have low homology to the ERK1-III peptide
and would not be expected to be reactive with ERK1-III an-
tibody. Immunoblotting of ERK1-III immunoprecipitates with
anti-JNK failed to detect JNK (not shown). JNKs are thus
unlikely candidate ERPs. Although p49 is in the general mo-
lecular weight range of ERK1, p49 and ERK1 are readily dis-
tinguishable in SDS-PAGE (not shown). ERPs p49, p38, p36,
and p33 are plausibly within the molecular weight range of the
p38 MAPKs; however, ERPs immunoprecipitated with ERK1-
III fail to display reactivity when immunoblotted with specific
p38 MAPK antibodies (not shown). Several ERPs are also in
the molecular weight range of the ERK6 MAPK (38 kDa; alias
p38). Although we were able to detect ERK6 in cell extracts of
human A673 rhabdomyosarcoma cells, ERK6 was undetectable
in NE of HT29 cells. Although the p100 ERP is in the general
molecular weight range of ERK5/BMK1 (110 kDa; see Ref. 48),
the homology between the ERK1-III peptide and ERK5/BMK1
is relatively weak. The p65 ERP is in the general molecular
weight range of ERK7, a 61-kDa protein (21). The possibility
that p65 is ERK7 cannot be ruled out, although the homology of
ERK7 to the ERK1-III peptide sequence is weak. Taken to-
gether from these data it appears that, with the exception of
ERK2, most if not all of the ERPs bound to AP-1 are previously
unidentified proteins rather than known MAP kinases.
ERK2 forms stable complexes in vivo with AP-1. However,
the observation that multiple additional proteins immunologi-
cally related to MAP kinases bind AP-1 proteins in vivo is both
unique and perplexing. To explain the multiplicity and stability
of these complexes and understand their functions, we postu-
lated that AP-1 and ERPs form regulatory higher order com-
plexes at the transcriptional regulatory site of AP-1 DNA bind-
ing. The first prediction of this hypothesis is that ERPs will be
detectable in association with the AP-1 DNA along with AP-1
proteins.
Our initial efforts to detect ERPs in AP-1DNA complexes
were to perform electrophoretic mobility supershift assays with
radiolabeled AP-1 DNA oligonucleotides and anti-ERK anti-
bodies. No supershift was observed (not shown). Since the
absence of a supershift is not evidence that an antigen is absent
from a complex, we sought to develop an alternative means of
assaying for protein-DNA interactions on a micro scale. The
method of preparative DNA affinity chromatography (1, 49)
was adapted to an analytical scale to detect ERPs in association
with the AP-1 DNA-binding site. A single step batchwise affin-
ity chromatographic method was devised for whole nuclear
extracts (NE) using affinity beads attached to AP-1 DNA. This
is followed by SDS-PAGE and immunoblotting with anti-AP-1
and anti-MAPK antibodies.
Initial immunoblotting assays to test the efficacy of the bind-
ing assay were performed with AP-1 antibodies. AP-1 binding
to the beads was demonstrated by immunoblotting of Laemmli
SDS-PAGE gels with a mixture of antibodies against the AP-1
subunits c-Jun, JunB, and JunD (Fig. 2A). c-Jun and JunD
were detected in association with AP-1 DNA on the affinity
beads. Association of JunB was undetectable. Expression of
c-Jun and JunD but not JunB proteins was also detected in
unfractionated NE (not shown).
The NAPSTER Assay, an Analytical Scale Assay for Specific-
DNA Interactions—To ascertain the binding specificity of AP-1
and associated proteins, we devised a simple assay that we
term the NAPSTER assay. The assay enables identification of
proteins that interact specifically with the DNA-binding site on
the affinity beads and distinguish these from proteins that bind
nonspecifically. In the NAPSTER assay, nuclear extracts are
either directly subjected to DNA affinity chromatography or
are preincubated with wild type (wt) or mutant (mut) AP-1
oligo prior to batchwise DNA affinity chromatography. For
analyses of AP-1 composition, samples from NAPSTER isola-
tion are subsequently subjected to Laemmli SDS-PAGE and
Western immunoblotting with anti-AP-1 antibodies. One would
predict that proteins that bind specifically to the AP-1 DNA-
binding site will undergo specific competition by wt but not mut
oligo, whereas proteins that bind nonspecifically will not be
competed differentially by the two sequences. By these means
specific binding of c-Jun and JunD to the AP-1 DNA-binding
site was detected, thus demonstrating the efficacy of the
NAPSTER assay method (Fig. 2A). Specific binding to AP-1
DNA-binding sites from two different genes, the Gibbon ape
leukemia virus long terminal repeat (GALV-LTR) and human
FIG. 1. ERK2 and several other ERK-related proteins interact
in vivo with multiple AP-1 transcription factor subunits. Immu-
noprecipitations were performed with whole cell extracts from in vivo
metabolically 35S-labeled JB6 and HT29 cells with the indicated anti-
bodies. Panel 1, A–C, JB6 cells. A, PAN-ERK (ERK1-III); B, PAN-
ERK  preincubated ERK1-III competitor peptide; C, cFos-(75–155).
Panel 2, A–D, JB6 cells; E, HT29 cells. A, ERK1/2 1B3B9; B, ERK1-
III (PAN anti-ERK MAP kinase); C, Fra-1-(1–276); D, c-Jun-(948-
4); E, c-Jun-(948-4). For this and all subsequent figures, Mr is for
molecular weight standards.
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collagenase I, was demonstrated (Fig. 2 and data not shown).
The typical yield of Jun proteins bound to the beads relative to
that present in unfractionated NE was between 30 and 50%.
Association of AP-1 with DNA on the beads was blocked as a
function preincubation with increasing concentrations of wt
AP-1 oligo but not mut oligo (Fig. 2, B and C).
To determine which AP-1 family members participate in
these complexes, we analyzed the material bound to the AP-1
DNA beads by Laemmli SDS-PAGE/Western with antibodies
against all seven AP-1 subunits. Binding to AP-1 DNA was
detected for JunD, c-Jun, c-Fos, Fra-1, and Fra-2 but not for
JunB or FosB (Fig. 2D). Western analyses of whole NE detected
expression of the AP-1 components that bind the DNA but did
not detect expression of JunB and FosB, even when large
quantities were loaded (not shown). Specificity of Western de-
tection was verified since preincubation of antibodies with their
cognate antigenic peptides inhibited their detection, whereas
preincubation with unrelated peptide sequences did not (not
shown).
ERK-related Proteins p41 and p44 Associate with the AP-1
DNA-binding Site—To test the prediction that ERPs associate
along with AP-1 DNA, we performed the NAPSTER assay and
immunoblotted associated proteins with the PAN-ERK anti-
body ERK1-III. Three major proteins were detected with mo-
lecular masses of 41, 44, and 39 kDa. Of these three bands, two
proteins, p41 and p44, associated specifically with the AP-1
DNA-binding site, since binding was specifically blocked when
wild type AP-1 oligonucleotide was preincubated with nuclear
extract, whereas mutant oligo had no effect (Fig. 3A). The
39-kDa protein bound to the beads in the presence of wild type
AP-1 oligo, indicating that its binding to the AP-1 beads was
nonspecific. Furthermore, as shown in Fig. 3B, p41 and p44
proteins are specifically recognized by the antigen-binding site
within the PAN-ERK antibody, since preincubation of ERK1-
III antibody with the ERK1-III peptide antigen but not a het-
erologous peptide antigen (from the ERK3 protein) blocked the
association of p44 and p41 with the PAN-ERK antibody. By
these criteria we refer to p44 and p41 as ERK-related proteins
(ERPs). Therefore, by the NAPSTER assay, ERP proteins as-
sociate along with AP-1 proteins with the AP-1 DNA. Since the
molecular weights of p41 and p44 are readily distinguishable
from the class I ERPs, we designate them as class II ERPs.
Although the class I ERPs were detectable with ERK1-III in
Western blots as well as immunoprecipitations, they were not
found in association with DNA, even when 1.5 mg of input NE
was run in NAPSTER assays (not shown). Therefore class II
but not class I ERPs associate with DNA along with AP-1.
Furthermore, class I but not class II ERPs were detectable in
association with AP-1 proteins in the absence of DNA.
ERK3-related Protein p97 Associates with AP-1 DNA-binding
Site—We extended our search for potential ERPs that associate
with the AP-1 DNA-binding site by performing the NAPSTER
assay and immunoblotting with additional anti-MAPK anti-
bodies. Among these was an antibody that recognizes human
p97/ERK3. By these means a 97-kDa protein was detected in
specific association with the AP-1 DNA-binding sequence (Figs.
4 and 5B). As for p41 and p44, p97 was detected bound to the
AP-1 DNA beads if nuclear extracts were directly subjected to
DNA affinity chromatography, or if they were preincubated
FIG. 2. AP-1 dimers from HT29 adenocarcinoma cell nuclei
interact specifically with affinity beads containing the AP-1
DNA and contain multiple Jun and Fos partners. A, AP-1 dimers
bind specifically to AP-1 affinity beads in the NAPSTER assay. HT29
cells were treated for 90 min with TPA, and NE were prepared from
harvested cells. DNA affinity chromatography with 30 g of protein
from whole NE was either performed directly () or after preincubation
with a 2.5-fold molar excess of wild type (wt) or mutant (mut) AP-1
oligonucleotides derived from the GALV-LTR. NE (5 g) directly loaded
in SDS-PAGE. NE, , wt, and mut nomenclature are also used for
NAPSTER assays in all subsequent figures. Proteins bound on the DNA
affinity beads were run in SDS-PAGE by direct loading of beads boiled
in SDS sample buffer. Proteins were transferred by Western blot and
immunoblotted with a mixture of specific antibodies against c-Jun,
JunB, and JunD (1 g/ml each). c-Jun and JunD are shown with
arrows. B and C, titration competition in the NAPSTER assay demon-
strates specific binding of AP-1 transcription factor to AP-1 DNA beads.
B, lane C, control incubation of NE  beads without preincubated free
oligos. Numbers above the triangles indicate increasing concentrations
of free wild type (wt) or mutant (mut) oligo, expressed as fold molar
excess of free oligo relative to bound wt oligo on beads. Bracket indicates
signal of JunD proteins in Western/ECL immunodetection. C, quanti-
tation of B. Similar results for quantitative preincubation were ob-
tained in three independent experiments; graphed results are from a
representative experiment. D, AP-1 bound to beads contains c-Jun,
JunD, c-Fos, Fra-1, and Fra-2 but not JunB or FosB. DNA affinity
chromatography was performed, and affinity beads containing bound
AP-1 were directly loaded in SDS-PAGE and subjected to Western
transfer and immunoblotting with specific antibodies against each of
the seven AP-1 transcription in a multiscreen apparatus (Bio-Rad).
FIG. 3. ERK-related proteins p41 and p44 associate along with
AP-1 at the AP-1 DNA-binding site. A, NAPSTER assay with
ERK1-III. NE, nuclear extract directly loaded in SDS-PAGE. NE
directly loaded in SDS-PAGE. Samples were eluted by boiling beads in
SDS sample buffer, loaded in SDS-PAGE, and subjected to Western
transfer and immunoblotting with the PAN-ERK antibody ERK1-III
using 2 g/ml ERK1-III antibody. B, ERK1-III antibody specifically
detects p44 and p41 ERPs. 1 mg of NE per NAPSTER assay sample was
subjected to AP-1 DNA affinity chromatography, run in SDS-PAGE,
transferred by Western blot, and immunoblotted with ERK1-III anti-
body that had been preincubated with a 25-fold molar excess of anti-
genic peptide (pep), “nonspecific” peptide (ns against amino acids
303–325 of rat ERK3), or no peptide (). C, ERPs p41 and p44 are not
the MAP kinases ERK1 and ERK2. 375 g of NE per sample were
subjected to the NAPSTER assay. Proteins were visualized by immu-
noblotting with ERK1 antibody (which recognizes ERK1 and ERK2).
ERK1 and ERK2 proteins are indicated with arrows.
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with mut AP-1 oligo, but not if they were preincubated with wt
AP-1 oligo. Antibody preincubation with antigenic ERK3 D23
peptide (amino acids 303–325 of rat ERK3) abolished detection
of p97, whereas preincubation with a heterologous peptide
(amino acids 353–567 of rat ERK3) did not. Therefore, p97 is an
ERP that interacts specifically with the AP-1 DNA sequence.
We refer to p97 as a class III ERP.
ERPs p44 and p41 Are Not ERK1 or ERK2—p44 and p41
have apparent molecular weights close to the MAP kinases
ERK1 and ERK2, and ERK1-III is capable of recognizing
ERK1 and ERK2 (50) (Fig. 3A, lane NE). We therefore sought
to determine whether p44 and p41 are ERK1 and ERK2. To do
this we performed the NAPSTER assay and immunoblotted
with a second anti-ERK1 antibody that specifically recognizes
ERK1 and ERK2 but is not a PAN-ERK antibody (sc-93, Santa
Cruz Biotechnology). Whereas ERK1 and ERK2 were readily
detected in nuclear extracts, no signal was detected in material
bound to the AP-1 beads, either in the presence or absence of
preincubation with unbound oligo (Fig. 3C). Whereas ERK1-
III detects ERK1 and ERK2 less strongly than the specific
ERK1 antibody (compare nuclear extract samples from the
two antibodies, NE lanes in Fig. 3, A versus C), only ERK1-III
detects p41 and p44. These data demonstrate that p41 and p44
are not ERK1 or ERK2.
ERPs that Associate with the AP-1 DNA-binding Site Are
New Species and Are Not Conventional MAP Kinases: MAP
Kinase Proteins p38, p38, JNK1/SAPK, JNK2/SAPK,
JNK3/SAPK, ERK5/BMK1, and p38/ERK6/SAPK3 Are
Not Detected in Association with AP-1DNA Complexes—After
finding that ERK1 and ERK2 do not associate with AP-1DNA
complexes, we investigated the possibility that other MAP ki-
nase species specifically associate with the AP-1 DNA. Protein
expression was assayed directly by Western analyses of whole
NE, and DNA binding was assayed by the NAPSTER assay.
Strong expression of p38 and/or p38, JNK1/SAPK, JNK2/
SAPK, and/or JNK3/SAPK, and weak expression of ERK5/
BMK1 proteins was detected in HT29 nuclear extracts. How-
ever, no specific association of these proteins with AP-1 DNA
beads was detectable, even when 400 g of input protein per
sample were used in the NAPSTER assay (not shown). p38/
ERK6/SAPK3 was not detectable in HT29 NE or bound to AP-1
DNA beads in NAPSTER assays even when as much as 1 mg of
input NE was tested (not shown).
The 97-kDa ERK3-related Protein Is Not Human p97/
ERK3—The 97-kDa protein human p97/ERK3 contains an
epitope recognized by the ERK3 D23 antibody. Therefore, when
we detected a protein of 97 kDa associated with AP-1 and DNA,
our initial hypothesis was that it was the human 97-kDa pro-
tein p97/ERK3 (hERK3). To test this we performed the
NAPSTER assay with several additional antibodies against
diverse epitopes within hERK3. None of the additional anti-
bodies detected a specific signal in the vicinity of 97 kDa. To
determine whether this was due to a lack of sensitivity of these
antibodies or to the absence of the predicted ERK3 epitopes in
p97, we expressed bacterial recombinant hERK3 protein (15),
and we compared the Western detectability of recombinant
hERK3 to that of affinity-purified cellular p97 from the NAP-
STER assay.
Full-length recombinant hERK3 protein (rhERK3) from bac-
terial extracts was readily detectable by Coomassie staining
(Fig. 5A) and by Western immunoblotting with several anti-
bodies against distinct epitopes in hERK3 (Fig. 5, B–D).
rhERK3 ran as a protein with a molecular mass of 105 kDa,
compared with an apparent molecular mass in SDS-PAGE of
97 kDa reported by Zhu et al. (15). p97 isolated from NE and
detected by ERK3 D23 migrated faster than the recombinant
p97/hERK3 (Fig. 5B). However, whereas the other two ERK3
antibodies also detected rhERK3, they failed to detect a specific
band isolated in the NAPSTER assay in the molecular mass
range of p97, even when 400 g of NE was used per sample
(Fig. 5, C and D). A protein that ran in the vicinity of ERK3 but
somewhat more slowly at 110 kDa (“p110”) was detected in
nuclear extracts with anti-ERK3-C and anti-ERK3-F (Fig. 5, C
and D). This may be a posttranslationally modified (perhaps
phosphorylated) form of hERK3. Detection of rhERK3, p97,
and p110 was specifically competed with specific but not het-
erologous peptides when immunoblotted with all three ERK3
antibodies (not shown). Taken together these data do not sup-
port the hypothesis that the p97 protein that associates with
the AP-1 DNA-binding site is the human p97/hERK3 protein.
To determine more definitively whether p97 and ERK3 are
the same or different proteins, we isolated rhERK3 and p97
and performed comparative V8 protease mapping. p97 was
isolated by DNA affinity chromatography of 20 mg of protein
from whole nuclear extract. Isolated p97 and p97/hERK3 from
bacterial extracts were gel-purified by excision of isolated
bands in SDS-PAGE and digested with endoproteinase Glu-C
(“V8 protease”). As shown in Fig. 5E, the V8 digestion patterns
of p97 and rhERK3 are strikingly different. Distinct V8 diges-
tion patterns for p97 and rhERK3 were observed even when a
variety of V8 protease concentrations was tested (not shown).
These data demonstrate that p97 is not human p97/ERK3.
Immunoprecipitates Containing AP-1 and ERPs Contain Ki-
nase Activity, but No Kinase Activity Is Detected in Association
with AP-1 DNA—To determine whether immune complexes
containing AP-1 and ERPs may contain stably associated ki-
nase activity, we performed in vitro kinase reactions using the
classic MAP kinase substrate MBP. As shown in Fig. 6, im-
mune complexes isolated by immunoprecipitation from NE
with c-Jun, c-Fos, and JunD contained MBP kinase activ-
ity. As expected, immunoprecipitates isolated with an antibody
against ERKs 1 and 2 (PAN- ERK antibody ERK1-III; Fig. 6),
and against ERK3 (ERK3 D23, Fig. 6, and ERK3 I15; not
shown) also displayed kinase activity. Kinase activity for sam-
ples immunoprecipitated with AP-1 and ERK antibodies was
significantly higher than control samples incubated with nor-
mal rabbit serum (for antibodies against full-length proteins)
or for peptide antibodies when preincubated with excess pep-
tide antigen competitor before immunoprecipitation (not
shown). We conclude that kinase activity is stably associated
with intracellular AP-1 transcription factors.
To explain the presence of multiple ERPs in complexes with
FIG. 4. The ERK3-related protein p97 associates specifically
with AP-1 DNA affinity beads. The NAPSTER assay was performed
using 300 g of protein from NE per sample. Controls for specific
detection of p97 protein by anti-ERK3 D23 antibody were performed by
antibody preincubation with 25-fold molar excess of competitor peptide.
Pep, immunoblotting performed without preincubation of ERK3 D23
antibody with peptide. Pep, preincubation with D23 peptide. NS,
preincubation with I15 peptide (amino acids 353–367 of rat ERK3).
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AP-1, we hypothesized that they participate in AP-1DNA com-
plexes and regulate transcriptional activation by AP-1, perhaps
by phosphorylating Jun and Fos family members and/or other
DNA-binding proteins proximal to the AP-1 DNA-binding site.
An initial prediction of this hypothesis is that kinase activity
will be detected in association with the AP-1 DNA. To test this
hypothesis, kinase activity assays of NAPSTER-isolated pro-
tein complexes associated with AP-1 DNA was performed.
Bound proteins were eluted with wt AP-1 oligo to eliminate
nonspecific kinase activity bound to the beads. Protein kinase
assays were performed on the eluted proteins with various
substrates. The substrates tested were MBP (see Fig. 6), c-Jun,
JunD, c-Fos, histone H1, histone H3, and the C-terminal do-
main of RNA polymerase II (CTD), which is phosphorylated by
MAP kinases in vitro and whose phosphorylation modulates
RNA polymerase II transcriptional activity (51–53). No detect-
able kinase activity for any substrate tested was associated
with the AP-1 DNA-binding site, although specific association
of AP-1 subunits and ERPs with AP-1 DNA was detected in the
same experiments by Western blots, and positive control kinase
activity with recombinant enzymes was observed (ERK1 en-
zyme for MBP, CTD, and c-Fos substrates; PKC enzyme for
histone H1 and H3 substrates; JNK1 enzyme for MBP, c-Jun
and JunD substrates; Fig. 6 for MBP and data not shown). No
specific MBP kinase activity was detected in renatured kinase
assays (54) with MBP impregnated in SDS-PAGE gels, using
NAPSTER isolated material from 400 g of HT29 whole NE
(not shown). These data show that although kinase activity is
associated with AP-1 proteins when they are not bound to
DNA, it is lost upon DNA binding.
Association of c-Jun, p41, and p44 with AP-1 DNA Is TPA-
inducible but Association of JunD and p97 Is Not—We com-
pared the intracellular levels and association of AP-1, p41, p44,
and p97 isolated from NE in TPA-treated versus untreated cells
(Fig. 7A). Levels of c-Jun in the nucleus were TPA-inducible,
whereas levels of JunD were not. AP-1 DNA binding of JunD
and c-Jun correlated with levels of expression, with induction
of DNA binding observed for c-Jun but not JunD. Like c-Jun,
ERPs p44 and p41 showed significant increases in association
with DNA after TPA treatment. Since expression of p41 and
p44 was undetectable in nuclear extracts, it is not evident
whether the induced participation of p41 and p44 in the com-
plexes is due to induced expression of p41 and p44 proteins,
increased affinity for the AP-1 complex, or increased recruit-
ment by c-Jun protein within the complex, although we spec-
ulate that the latter may be the case. In contrast, the associa-
tion of p97 with DNA was not TPA-inducible, since the amount
of p97 associated with the AP-1 DNA-binding site was equal in
TPA-treated and untreated cells.
Identification of Multicomponent Class II ERP-AP-1
ProteinAP-1DNA Complexes—We hypothesized that class II
ERPs are docked to the DNA by the AP-1 dimer. However,
there also exists the possibility that association of ERPs with
DNA is independent of AP-1 proteins. To determine if DNA
association by ERPs is dependent or independent on AP-1
proteins, we immunodepleted nuclear extracts of AP-1 proteins
prior to AP-1 DNA affinity chromatography. Since Fos binds
the AP-1 DNA only when heterodimerized with Jun, depletion
of Jun subunits should abolish the binding of all AP-1 com-
plexes, and should also deplete proteins whose association with
the AP-1 DNA are dependent on AP-1 proteins. A single round
of immunodepletion with c-Jun plus JunD depleted 80–90%
of AP-1. Two rounds of depletion with these antibodies effi-
ciently depleted Jun subunits to levels that were virtually
undetectable (Fig. 7B). Two rounds of AP-1 immunodepletion
also eliminated association of p41 and p44 ERPs as evidenced
FIG. 5. The AP-1 DNA-associated protein p97 is not human ERK-3. A, expression of recombinant p97/ERK3 in bacteria. Extracts were
made from E. coli transformed with the bacterial expression construct pET3C-ERK3 encoding full-length ERK3. Samples were run in SDS-PAGE
and stained with Coomassie Blue. , no isopropyl-1-thio--D-galactopyranoside induction; , with isopropyl-1-thio--D-galactopyranoside induc-
tion. B, specific detection of recombinant human ERK3 and p97 with anti-human ERK3 D23 antibody. ERK3 is against amino acids 303–325 of
rat ERK3. pep, without antibody preincubation with ERK3 D23 peptide; pep, with preincubation with D23 peptide. B–D, samples were run in
SDS-PAGE gels and immunoblotted. R, rhERK3, recombinant human p97/ERK3. C and D, endogenous human ERK3 is not detectable specifically
associated with AP-1 DNA. C, immunoblotting with anti-ERK3 C against amino acids 427–442 of rat ERK3; D, immunoblotting with anti-ERK3
F, a specific antibody against 543–721 of human p97/ERK3, an epitope in the C terminus of human p97/ERK3 that is not present in rat ERK3. *
in B–D denotes a band from nuclear extracts running slightly above recombinant ERK3 that is detected with anti-rat and anti-human ERK3
antibodies and may be native human ERK3. E, p97 is not p97/ERK3. p97 was isolated by AP-1 DNA affinity chromatography of 20 mg of whole
nuclear extract. p97 and recombinant human p97/ERK3 were pre-purified in SDS-PAGE. Comparative V8 protease digestion of p97 and rhERK3
isolated as gel slices from SDS-PAGE were performed. Gel slices for V8 protease digestion were overlaid with 0.04 units of endoproteinase Glu-C
(V8 protease), run through the gel, and subjected to Western transfer and immunoblotting with ERK3 D23 antibody. S, sample from DNA affinity
chromatography; R, rhERK3. Arrows indicate locations of digestion products.
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in Western immunoblotting with ERK1-III of NAPSTER-iso-
lated material (Fig. 7B). These data demonstrate that associa-
tion of p41 and p44 ERPs with the AP-1 DNA-binding site is
dependent upon the presence of AP-1 transcription factor.
Based on these data it is likely that p41, p44, and AP-1 form
multicomponent complexes at the AP-1 DNA-binding site.
Association of ERP p97 with DNA Is Independent of AP-1
Transcription Factors—We also performed immunodepletion to
test the hypothesis that p97 participates in a multicomponent
complex with AP-1 protein and AP-1 DNA. NAPSTER assays
were performed with double depleted NE and immunoblotted
with ERK3 D23 antibody. There was no decrease in the
amount of p97 specifically associated with AP-1 DNA in ex-
tracts that had undergone two rounds of immunodepletion of
AP-1, relative to undepleted samples (Fig. 7B). This suggested
that association of p97 is independent of AP-1 proteins. After
two rounds of depletion Jun subunits were undetectable,
whereas some Fos family subunits were still detectable (most
likely due to greater sensitivity of the Fos antibody). To rule out
the possibility that p97 was associating indirectly with AP-1
DNA via residual undepleted AP-1, or in a manner uniquely
Fos-dependent but Jun-independent, we performed three
rounds of depletion with antibodies against both Fos family
and Jun family proteins. AP-1 DNA affinity chromatography
showed that c-Fos, Fra-1, Fra-2, and JunD were depleted to
undetectable levels in the triple depleted samples (Fig. 7C).
Association of p97 with DNA was unaffected by complete de-
pletion of Jun and Fos subunits. These data demonstrate that
specific association of p97 with AP-1 DNA-binding site is inde-
pendent of AP-1 protein binding. The class III ERP p97 is thus
distinguishable from the other ERP classes by virtue of its
relatedness to ERK3 (rather than ERK2) and its association
with DNA in the absence of AP-1 proteins.
DISCUSSION
In this report we describe 10 ERK-related proteins that
consist of three distinct classes of proteins. These classes are
defined by differences in their interactions with AP-1 proteins
and the AP-1 DNA-binding site. As summarized in Table I,
class I ERPs are ERK1/2-related proteins that bind in vivo with
AP-1 proteins but do not associate with the AP-1 DNA. Class II
ERPs, also ERK1/2-related, bind to AP-1 proteins and associate
with AP-1 DNA in a manner that is dependent upon AP-1
proteins. The class III ERP p97 is related to ERK3 and associ-
ates with the AP-1 DNA without evidence of association with
AP-1 proteins. Both class II and class III ERPs may interact
with DNA either indirectly via protein-protein contacts or di-
rectly with the DNA. We have also designated a number of
MAP kinase superfamily members as class IV MAPKs based
upon the observation that they are not detected in stable asso-
ciation with AP-1 proteins or AP-1 DNA in the NAPSTER
assay system. These include the MAPKs ERK1, ERK3, ERK4,
ERK5/BMK, and ERK6. In our studies, JNK1 and JNK2 also
qualify as class IV ERPs, although other laboratories have
detected JNK-Jun associations in coimmunoprecipitation as-
says when epitope-tagged genes encoding AP-1 and JNK com-
ponents were transiently overexpressed in cultured cells (22–
23, 25, 55, 56). Since JNKs are kinases for Jun, such
interactions are to be expected and may be transient in nature,
since coimmunoprecipitation of endogenously expressed JNKs
and Juns have not been observed by our group or reported by
others.
We have detected a diverse variety of AP-1 transcription
factor subunits in association in vivo with an equally diverse
variety of class I ERPs. The detection of multiple Jun and Fos
subunits in these complexes is a new observation. AP-1 sub-
units found in association with ERPs include c-Jun, JunD,
c-Fos, Fra-1, and Fra-2. Only JunB and FosB were not detected
in these complexes. The variety of ERPs in the complexes
includes the following seven proteins: p100, p65, p49, p38, p36,
p33, and the MAP kinase ERK2. ERPs were detected in asso-
ciation with AP-1 in both mouse epidermal JB6 cells and hu-
man HT29 colon carcinoma cells. Since AP-1 complexes are
dimers of Jun-Fos or Jun-Jun family members, these data
indicate that many different types of AP-1ERP complexes are
present in cells and that the existence of these complexes
occurs in cell types originating from different tissues, both
cancerous and noncancerous.
What are the functions of these complexes? Why do so many
different types of ERPs and AP-1 dimers interact with one
another, and why are the complexes so stable? If the interac-
FIG. 6. AP-1 has stably associated kinase activity when not
bound to AP-1 DNA. Immunoprecipitations with 750 g of whole cell
extract or dialyzed HT29 NE were performed with antibodies against
MAP kinases or AP-1, and in vitro kinase assays were performed with
MBP as described under “Experimental Procedures.” Specificity con-
trols consisted of peptide antibody samples preincubated with antigenic
competitor peptides prior to immunoprecipitation. Controls for antibod-
ies for which no peptide competitor was available consisted of preincu-
bations with normal rabbit serum (NRS), followed by protein A precip-
itations. AP-1 DNA affinity chromatography with 600 g of NE was
performed by preincubation with mutant AP-1 DNA beads followed by
wild type beads as described above. Kinase activity was quantitated by
liquid scintillation counting of incorporated 32P into MBP. For immu-
noprecipitates, quantitation is expressed as fold induction relative to
newborn calf serum (for c-Jun and c-Fos) or to immunoprecipitates
with antibody preincubated with antigenic peptide (for ERK3, PAN-
ERK, and JunD). For samples isolated by DNA affinity chromatogra-
phy, fold induction is expressed relative to NAPSTER isolated samples
for which NE was preincubated with excess free wild type AP-1 oligo.
Samples from left to right: NRS, nonimmune rabbit serum; ERK3 D23;
PAN-ERK (ERK1-III); c-Jun-(948-4); c-Fos (Upstate Biotechnolo-
gies, Inc.); JunD SC; proteins associated with AP-1 DNA.
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tion between ERP and AP-1 is only that of an enzyme and
substrate, the observed multiplicity of stable protein-protein
interaction would not be expected. To address this paradox we
formulated a hypothesis that we have called the ERP-AP-1
docking hypothesis. By this hypothesis, AP-1 and ERPs form
functional higher order complexes at the site of AP-1 DNA
binding and regulate gene transcription by modulating com-
munication with other transcription factors or accessory factors
proximal to the AP-1 DNA-binding site via protein phosphoryl-
ation and/or protein-protein interactions. The first prediction of
the hypothesis is that ERPs will be detectable in association
with AP-1 proteins bound at the AP-1 DNA-binding site. Stud-
ies in other laboratories have shown that when bound to DNA,
AP-1 can interact with neighboring DNA-binding proteins
within the regulatory promoter region, including Smad pro-
teins (57), Ets proteins (58), and NFAT (59, 60). However, to
date no proteins related to ERK MAP kinases have been found
in association with AP-1 at the DNA-binding site.
To test this prediction we performed the NAPSTER assay
and identified three proteins that associate with the AP-1
DNA: the class II p41 and p44 proteins, immunologically re-
lated to ERK1 and ERK2 MAPKs, and the class III p97 protein,
immunologically related to ERK3 MAPK. Whereas p97 associ-
ated with DNA independently of AP-1 proteins, association of
p41 and p44 required AP-1 proteins, suggesting the presence of
p41 and p44 in higher order complexes with AP-1 and DNA.
The class II p41 and p44 proteins thus fulfill the first prediction
of the ERP-AP-1 docking hypothesis. NAPSTER screening
demonstrated no detectable binding of known MAPK proteins
at the AP-1 DNA-binding site, including MAPKs ERK1, ERK2,
FIG. 7. A, association of c-Jun, p41, and p44 with AP-1 DNA is TPA-inducible, whereas association of JunD and p97 is not. HT29 cells were
treated with TPA () or with Me2SO control () for 90 min prior to harvest and NE preparation. 100 g of NE (for c-Jun and JunD detection), 3.3
mg of NE (for p41 and p44 detection), or 1.1 mg of NE (for p97 detection) were subjected to AP-1 DNA chromatography followed by Western
analyses with c-Jun, JunD, PAN-ERK, and ERK3 D23 antibodies. c-Jun, JunD, p41, p44, and p97 are indicated by arrows or brackets. B,
association of p44 and p41 ERPs with DNA is dependent on AP-1 proteins. Nuclear extracts underwent mock immunodepletion (C, control with
no antibody) or two rounds of immunodepletion (D) with a mixture of c-Jun and JunD antibodies, prior to the NAPSTER assay. Western analyses
were performed with immunodepleted NAPSTER assay samples: top panel, Juns; middle panel, ERK1-III; bottom panel, ERK3 D23. 120 g
per NAPSTER assay sample of NE with respect to protein was used for PAN Jun, and 1.2 mg per sample was used for ERK1-III and ERK3
D23. JunD, c-Jun, p41, p44, and p97 are indicated with arrows. Similar results were obtained in two independent experiments. C, association of
p97 ERP is independent of AP-1 proteins. Nuclear extracts underwent mock immunodepletion (C) or three rounds of immunodepletion (D) with
a mixture of antibodies against all seven AP-1, and were subsequently subjected to AP-1 DNA affinity chromatography, loaded in SDS-PAGE, and
subjected to Western immunoblotting with ERK3 D23 (upper panel), JunD (lower left panel), or Fos antibody that recognizes multiple Fos
family proteins (lower panel). 180 g of NE per sample with respect to protein was used for DNA affinity chromatography for PAN Jun, and 1.8
mg per sample was used for ERK1-III and ERK3 D23. p97 and c-Fos are indicated by arrows, and JunD, Fra-1, and Fra-2 are indicated by
brackets.
TABLE I
Four classes of ERPs
Proteins Binds AP-1proteins
Association with AP-1 DNA Related
immunologically
to
Associated
kinase activityAP-1 protein-
dependent
AP-1 protein-
independent
Class I, 7 proteins Yes N.O.a N.O. ERK1/2 Yes
p33, p36, p38, ERK2, p49, p65, p100
Class II, 2 proteins Yes Yes N.O. ERK1/2 N.O.
p41, p44
Class III, 1 protein N.O. N.O. Yes Human ERK3 N.O.
p97
Class IV
ERK1, ERK3, ERK4, ERK5/BMK1, ERK6, Jnk1, Jnk2 N.O. N.O. N.O. ERKs and Jnks Yes
a N.O., not observed.
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ERK3, ERK5/BMK, ERK6, p38, JNK1, and JNK2. As described
above, with the exception of ERK2, none of these proteins were
detected in association with AP-1 dimers in the absence of DNA
either.
ERPs p100, p65, p49, p38 (which is not MAPK p38; see
“Results”), p36, p33, and ERK2 are detected in association with
AP-1 proteins by coimmunoprecipitation under solution condi-
tions that are unfavorable to protein-DNA interactions, and
these proteins were not detected in association with AP-1 DNA
in the NAPSTER assay. Based upon their molecular weights
(with the exception of ERK2, which also has been ruled out; see
Fig. 3C), these ERPs and p41 and p44 are different proteins.
We detected no evidence of p41 and p44 bound to AP-1 proteins
in the absence of DNA.
The second prediction of the ERP-AP-1 docking hypothesis is
that we should detect kinase activity in association with AP-1
proteins bound to DNA. This prediction was not borne out. We
detected kinase activity associated with AP-1 proteins only
when AP-1 proteins were not bound to DNA. While the possi-
bility cannot be ruled out that kinase activity is associated with
AP-1 DNA that was not detected due to the wrong choice of
substrate or insufficient quantities of enzyme, this appears
improbable since many substrates were tested, and NAPSTER
kinase assays were performed with large quantities of starting
material.
It is likely that ERK2 is a major source of AP-1 protein-
associated kinase activity from AP-1 immunoprecipitates since
ERK2 is the only one of the ERPs associated with AP-1 that
had measurable kinase activity in renatured kinase assays
with impregnated myelin basic protein substrate.2 Kinase ac-
tivity either falls off of AP-1 dimers or is turned off upon
association with DNA. We consider the former possibility more
likely since ERK2 is detected in association with AP-1 proteins
only when they are not bound to the DNA. From these data our
new working hypothesis is that the class I ERPs including
ERK2 kinase activity are bound to AP-1 in the absence of DNA,
and they disengage from AP-1 and are replaced by the class II
ERPs p41 and p44, thus forming a new higher order complex
when AP-1 proteins bind the DNA. We also hypothesize that
class II p41 and p44 ERPs associate with DNA in a manner
that is dependent upon c-Jun rather than JunD, since p41, p44,
and c-Jun but not JunD exhibit TPA-dependent induction of
DNA binding. We speculate that the class I ERPs that bind
AP-1 in the absence of DNA function to repress its DNA bind-
ing and that the class II ERPs that associate along with AP-1
proteins with the DNA modulate its transactivating function.
Future experiments will be done to test these notions. It is
unclear how many of these respective components compose
these protein-protein and protein-DNA complexes or whether
the contacts of class II ERPs with DNA are direct or indirect.
Further studies involving molecular cloning of the genes en-
coding these numerous class I and class II proteins, and other
studies to identify DNA-binding proteins proximal to the AP-1
DNA-binding site with which functional interactions with
ERPs may be occurring, are ongoing to address these interest-
ing questions.
In initial experiments on this project we attempted to detect
evidence of ERP-AP-1 DNA interactions with gel supershift
assays employing the ERK1-III antibody, but none were de-
tectable under a variety of assay conditions.2 In hopes of cir-
cumventing this problem, we devised the small scale specifici-
ty-controlled NAPSTER assay, adapted from large scale DNA
affinity chromatography. The assay succeeded in identifying
two proteins cross-reactive with ERK1-III that were missed
by the gel supershift method. The NAPSTER assay is per-
formed at much higher concentrations of protein and DNA than
the gel shift assay, and so may more effectively promote the
stability of specific low affinity interactions and multicompo-
nent protein-DNA complexes. Because the NAPSTER assay is
rapid, specific, and capable of detecting interactions that are
missed by gel supershift assays, we believe that it will be useful
to investigators as an alternative method for studying protein-
DNA interactions on an analytical scale. We also expect that
the assay will be generally applicable to transcription factors
other than AP-1 and to other DNA-binding proteins.
As indicated above, several laboratories (22–23, 25, 55–56,
59) have detected physical associations between Jun kinases
and Jun proteins, in in vitro assays, by immunoprecipitation of
epitope-tagged transiently cotransfected c-Jun and JNK pro-
teins in cultured cells and by yeast and mammalian two-hybrid
analyses. c-Jun amino acid sequences involved in these inter-
actions include amino acids 31–47, a region that is deleted in
v-Jun (55), and the C-terminal region between amino acids 182
and 256 (56). Gel mobility shift assays performed by May et al.
(56) employing an AP-1 DNA oligonucleotide and high concen-
trations of purified recombinant c-Jun and JNK-1 proteins
suggested the possibility of ternary complexes of AP-1, JNK,
and DNA. However, appropriate mutant AP-1 oligonucleotide
controls for DNA binding were not performed in these experi-
ments, so a specific requirement for the AP-1 consensus DNA
sequence for JNK binding was not demonstrated. In our hands
using the NAPSTER assay, although JNK bound DNA contain-
ing an AP-1 sequence, binding was nonspecific since preincu-
bation with wild type oligos failed to block JNK binding (not
shown).
Some comparisons may be made between the MAP kinase
BMK5/ERK1 and class I or class II ERPs. Recently, several
laboratories (61–63) have found that ERK5/BMK1 is a regula-
tor of MEF2 transcription factors. ERK5/BMK1 positively reg-
ulates gene transactivation by MEF2, phosphorylates MEF2 in
vitro, and physically interacts with MEF2. Although binding
interactions with MEF2-ERK5BMK1 complexes to DNA have
not been demonstrated, a transactivation domain in ERK5/
BMK1 has been identified that modulates MEF2 gene trans-
activation, and the kinase domain within ERK5/BMK1 is re-
quired for positive ERK5/BMK regulation of MEF2 activity. If
ERK5/BMK were to associate along with MEF2 with DNA, it
would fall into a different functional class than class I or class
II ERPs since in the latter cases kinase activity is observed only
in ERPs that are not associated with DNA.
Recent work by Janulis et al. (64) has uncovered a new MAP
kinase-related protein which is, like our class III ERP, named
p97, based upon its molecular weight. The p97 protein identi-
fied by Janulis et al. (64) is detected by anti-phospho-ERK and
anti-PAN-ERK antibodies, has kinase activity, modulates
downstream Raf signaling, and binds to Raf protein. It is un-
likely that the p97 molecule discovered by Janulis et al. (64) is
the same molecule as our p97 because our p97 protein has no
kinase activity, and PAN-ERK antibodies do not cross-react
with our p97 protein.
The class III p97 protein stands out as the only ERP that is
immunologically related to ERK3, and the only one that asso-
ciates with the DNA without requiring the involvement of AP-1
proteins. To date, proteins in the general molecular weight
range of p97 have not been identified that associate with AP-1
DNA. Because p97 does not require AP-1 dimers to associate
with the DNA, we performed the NAPSTER assay to determine
whether other AP-1 superfamily members that can bind the
minimal AP-1 consensus sequence could have specifically
bound the AP-1 site along with a putative coassociated p97.2 L. Bernstein, unpublished data.
Ten ERK-related Proteins Bind AP-1 Proteins and/or AP-1 DNA 32371
 by guest on M
arch 31, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Specific binding of CREB, ATF, Maf, and other cap ‘n collar
AP-1 superfamily members to the AP-1 DNA was not detected.3
p97 therefore appears to be a novel species that either associ-
ates with the AP-1 DNA in the absence of other factors or binds
with other factors in a new multicomponent complex that has
not been described previously. It is possible that p97 is a new
transactivating or transrepressing protein that competes with
AP-1 for binding the AP-1 site. Future work, including molec-
ular cloning of p97, is ongoing to characterize the functions of
this interesting protein and any proteins that may be associ-
ated with it when it binds to the AP-1 DNA.
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